Mutually exclusive. Prices sum to 100%.
Rule
Resolves to whichever named GLP-1 telehealth brand FIRST publicly announces (via official channel, SEC filing, or named-source business press) that it will stop selling compounded semaglutide / tirzepatide in the United States, OR files for Chapter 7 or Chapter 11 bankruptcy on PACER, between 2026-05-31 and 2026-12-31. A pivot to "branded only / no compounded" counts as an exit from compounding for this market. Continued compounding under a "carve-out" or "shortage exemption" does NOT resolve any single brand YES. If no named brand exits by 2026-12-31, resolves to "None by Dec 31, 2026."
Source: Brand press release + SEC 8-K + PACER + CNBC/STAT/Fierce Healthcare
Resolves by Jan 7, 2027.
The FDA Pharmacy Compounding Advisory Committee meets in July 2026 to advise on restricting compounded semaglutide. Multiple telehealth brands have built billion-dollar businesses on compounded GLP-1s. When the regulatory squeeze tightens, operators argue which brand cracks first - the biggest target (Hims), the most-exposed mid-cap (Ro), or one of the smaller compounding-pharmacy plays.
